The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Open accessAbstract
BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis. METHODS: In two double-blind trials, we randomly assigned patients to receive secukinumab or placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks 0, 2, and 4, followed by subcutaneous secukinumab (150 mg or 75 mg) or matched placebo every 4 weeks starting at week 8. In MEASURE 2, a total of 219 patients received subcutaneous secukinumab (150 mg or 75 mg) or matched placebo at baseline; at weeks 1, 2, and 3; and every 4 weeks starting at week 4. At week 16, patients in the placebo group were randomly reassigned to subcutaneous secukinumab at a dose of 150 mg or 75 mg. The primary end point was the proportion of patients with at least 20% improvement in Assessment of Spondyloarthritis International Society (ASAS20) response criteria at week 16. RESULTS: In MEASURE 1, the ASAS20 response rates at week 16 were 61%, 60%, and 29% for subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respectively (P<0.001 for both comparisons with placebo); in MEASURE 2, the rates were 61%, 41%, and 28% for subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respectively (P<0.001 for the 150-mg dose and P=0.10 for the 75-mg dose). The significant improvements were sustained through 52 weeks. Infections, including candidiasis, were more common with secukinumab than with placebo during the placebo-controlled period of MEASURE 1. During the entire treatment period, pooled exposure-adjusted incidence rates of grade 3 or 4 neutropenia, candida infections, and Crohn's disease were 0.7, 0.9, and 0.7 cases per 100 patient-years, respectively, in secukinumab-treated patients. CONCLUSIONS: Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenous loading dose. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and NCT01649375.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Ware, J. E. (2000) · Spine · doi:10.1097/00007632-200012150-00008 · Cited by 4,455
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Braun, J., & Sieper, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60635-7 · Cited by 1,806
Self-citationSieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Hermann, K.-G., Landewé, R., Maksymowych, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.104018 · Cited by 1,652
Self-citationIL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151027 · Cited by 987
Self-citationvan der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Self-citationvan der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Self-citationHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Dougados, M., & Baeten, D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60071-8 · Cited by 780
Self-citationDavis, J. C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D. O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11325 · Cited by 754
Self-citationDevelopment of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
Doward, L. C., Spoorenberg, A., Cook, S. A., Whalley, D., Helliwell, P. S., Kay, L. J., McKenna, S. P., Tennant, A., van der Heijde, D., & Chamberlain, M. A. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.1.20 · Cited by 599
Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J. M., Landewé, R., Wordsworth, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61134-4 · Cited by 595
Self-citationInman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23969 · Cited by 593
Self-citationShen, H., Goodall, J. C., & Hill Gaston, J. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24568 · Cited by 516
Landewé, R., Braun, J., Deodhar, A. A., Dougados, M., Maksymowych, W. P., Mease, P. J., Reveille, J. D., Rudwaleit, M., van der Heijde, D. M. F. M., Stach, C. M., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204231 · Cited by 470
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
DeLay, M. L., Turner, M. J., Klenk, E. I., Smith, J. A., Sowders, D. P., & Colbert, R. A. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24763 · Cited by 404
Appel, H., Maier, R., Wu, P., Scheer, R., Hempfing, A., Kayser, R., Thiel, A., Radbruch, A., Loddenkemper, C., & Sieper, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3370 · Cited by 313
Self-citationBowness, P., Ridley, A., Shaw, J., Chan, A. T., Wong-Baeza, I., Fleming, M., Cummings, F., McMichael, A., & Kollnberger, S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002653 · Cited by 304
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Mazurov, V., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201601 · Cited by 293
Self-citationInterleukin‐17–positive mast cells contribute to synovial inflammation in spondylarthritis
Noordenbos, T., Yeremenko, N., Gofita, I., van de Sande, M., Tak, P. P., Caňete, J. D., & Baeten, D. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33396 · Cited by 270
Self-citationKenna, T. J., Davidson, S. I., Duan, R., Bradbury, L. A., McFarlane, J., Smith, M., Weedon, H., Street, S., Thomas, R., Thomas, G. P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33507 · Cited by 262
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Haibel, H., Rudwaleit, M., Listing, J., & Sieper, J. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.023176 · Cited by 222
Self-citationSong, I. ‐., Heldmann, F., Rudwaleit, M., Listing, J., Appel, H., Braun, J., & Sieper, J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27383 · Cited by 199
Self-citationvan der Heijde, D., Schiff, M. H., Sieper, J., Kivitz, A. J., Wong, R. L., Kupper, H., Dijkmans, B. A. C., Mease, P. J., & Davis, J. C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087270 · Cited by 188
Self-citationSieper, J., Porter-Brown, B., Thompson, L., Harari, O., & Dougados, M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203559 · Cited by 184
Self-citationTreatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
Song, I.-H., Heldmann, F., Rudwaleit, M., Haibel, H., Weiß, A., Braun, J. M., & Sieper, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.145946 · Cited by 168
Self-citationGlatigny, S., Fert, I., Marie-Agnès, B., Lories, R. J. U., Araujo, L. M. M., Chiocchia, G., & Bréban, M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33321 · Cited by 167
Krieg, P., Rosenberger, S. F., de Juanes, S., Latzko, S., Hou, J. L., Dick, A., Kloz, U., van der Hoeven, F., Haußer, I., Esposito, I., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.250 · Cited by 143
Sieper, J., Braun, J., Kay, J., Badalamenti, S., Radin, A. R., Jiao, L., Fiore, S., Momtahen, T., Yancopoulos, G. D., Stahl, N., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204963 · Cited by 127
Self-citation
Cited by
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210770 · Cited by 1,568
Self-citationThe IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Sieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Self-citationAnkylosing Spondylitis and Axial Spondyloarthritis
Taurog, J. D., Chhabra, A., & Colbert, R. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1406182 · Cited by 900
Rogler, G., Singh, A., Kavanaugh, A., & Rubin, D. T. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.042 · Cited by 869
Metadata
- Authors
- Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., Mpofu, S., & Richards, H. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-24
- Volume
- 373
- Issue
- 26
- Pages
- 2534-2548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2278932593
- Cited by
- 1,029
- References
- 33
- FWCI
- 70.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.